{"id":35538,"date":"2024-06-13T10:43:14","date_gmt":"2024-06-13T08:43:14","guid":{"rendered":"https:\/\/celonpharma.com\/?p=35538"},"modified":"2024-06-13T10:43:38","modified_gmt":"2024-06-13T08:43:38","slug":"current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend","status":"publish","type":"post","link":"https:\/\/celonpharma.com\/en\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\/","title":{"rendered":"Current report No. 7\/2024 \u2013 Opinion of the Supervisory\u2019s Board on the Management Board\u2019s recommendation on the payment of the dividend"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) \u2013 inside information.&nbsp;<br>Date: 24\/05\/2024, g.17:13<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In relation to the current report no. 5\/2024 of 23 May 2024 on Management Board&#8217;s recommendation on the payment of the dividend, the Management Board of Celon Pharma S.A. (\u201cCompany\u201d) hereby informs that on 24 May 2024 the Supervisory Board of the Company has given a positive opinion on the recommendation of the Management Board of Celon Pharma S.A. for the Ordinary General Meeting of the Company on the payment of the dividend referred to in the aforementioned report no. 5\/2024.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The final decision on coverage of the loss for the financial year 2023 and on payment of the dividend will be made by the Ordinary General Meeting of the Company.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) \u2013 inside information.&nbsp;Date: 24\/05\/2024, g.17:13 In relation to the current report no. 5\/2024 of 23 May 2024 on Management Board&#8217;s recommendation on the payment of the dividend, the Management Board of Celon Pharma S.A. (\u201cCompany\u201d) hereby informs that on 24 May 2024 the<a class=\"excerpt-read-more float-right\" href=\"https:\/\/celonpharma.com\/en\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\/\" title=\"ReadCurrent report No. 7\/2024 \u2013 Opinion of the Supervisory\u2019s Board on the Management Board\u2019s recommendation on the payment of the dividend\">Read more &raquo;<\/a><\/p>\n","protected":false},"author":31,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[46],"tags":[],"class_list":["post-35538","post","type-post","status-publish","format-standard","hentry","category-current-reports"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Current report No. 7\/2024 \u2013 Opinion of the Supervisory\u2019s Board on the Management Board\u2019s recommendation on the payment of the dividend - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Current report No. 7\/2024 \u2013 Opinion of the Supervisory\u2019s Board on the Management Board\u2019s recommendation on the payment of the dividend - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) \u2013 inside information.&nbsp;Date: 24\/05\/2024, g.17:13 In relation to the current report no. 5\/2024 of 23 May 2024 on Management Board&#8217;s recommendation on the payment of the dividend, the Management Board of Celon Pharma S.A. (\u201cCompany\u201d) hereby informs that on 24 May 2024 theRead more &raquo;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-13T08:43:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-13T08:43:38+00:00\" \/>\n<meta name=\"author\" content=\"Paulina Dobies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paulina Dobies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\\\/\"},\"author\":{\"name\":\"Paulina Dobies\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/e86806fa37010f6a01f6fc388950174b\"},\"headline\":\"Current report No. 7\\\/2024 \u2013 Opinion of the Supervisory\u2019s Board on the Management Board\u2019s recommendation on the payment of the dividend\",\"datePublished\":\"2024-06-13T08:43:14+00:00\",\"dateModified\":\"2024-06-13T08:43:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\\\/\"},\"wordCount\":143,\"articleSection\":[\"Current reports\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\\\/\",\"name\":\"Current report No. 7\\\/2024 \u2013 Opinion of the Supervisory\u2019s Board on the Management Board\u2019s recommendation on the payment of the dividend - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"datePublished\":\"2024-06-13T08:43:14+00:00\",\"dateModified\":\"2024-06-13T08:43:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/e86806fa37010f6a01f6fc388950174b\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Current report No. 7\\\/2024 \u2013 Opinion of the Supervisory\u2019s Board on the Management Board\u2019s recommendation on the payment of the dividend\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/e86806fa37010f6a01f6fc388950174b\",\"name\":\"Paulina Dobies\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Current report No. 7\/2024 \u2013 Opinion of the Supervisory\u2019s Board on the Management Board\u2019s recommendation on the payment of the dividend - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\/","og_locale":"en_US","og_type":"article","og_title":"Current report No. 7\/2024 \u2013 Opinion of the Supervisory\u2019s Board on the Management Board\u2019s recommendation on the payment of the dividend - Celon Pharma","og_description":"Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) \u2013 inside information.&nbsp;Date: 24\/05\/2024, g.17:13 In relation to the current report no. 5\/2024 of 23 May 2024 on Management Board&#8217;s recommendation on the payment of the dividend, the Management Board of Celon Pharma S.A. (\u201cCompany\u201d) hereby informs that on 24 May 2024 theRead more &raquo;","og_url":"https:\/\/celonpharma.com\/en\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\/","og_site_name":"Celon Pharma","article_published_time":"2024-06-13T08:43:14+00:00","article_modified_time":"2024-06-13T08:43:38+00:00","author":"Paulina Dobies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Paulina Dobies","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/celonpharma.com\/en\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\/#article","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\/"},"author":{"name":"Paulina Dobies","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/e86806fa37010f6a01f6fc388950174b"},"headline":"Current report No. 7\/2024 \u2013 Opinion of the Supervisory\u2019s Board on the Management Board\u2019s recommendation on the payment of the dividend","datePublished":"2024-06-13T08:43:14+00:00","dateModified":"2024-06-13T08:43:38+00:00","mainEntityOfPage":{"@id":"https:\/\/celonpharma.com\/en\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\/"},"wordCount":143,"articleSection":["Current reports"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\/","url":"https:\/\/celonpharma.com\/en\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\/","name":"Current report No. 7\/2024 \u2013 Opinion of the Supervisory\u2019s Board on the Management Board\u2019s recommendation on the payment of the dividend - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"datePublished":"2024-06-13T08:43:14+00:00","dateModified":"2024-06-13T08:43:38+00:00","author":{"@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/e86806fa37010f6a01f6fc388950174b"},"breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/current-report-no-7-2024-opinion-of-the-supervisorys-board-on-the-management-boards-recommendation-on-the-payment-of-the-dividend\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"Current report No. 7\/2024 \u2013 Opinion of the Supervisory\u2019s Board on the Management Board\u2019s recommendation on the payment of the dividend"}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/e86806fa37010f6a01f6fc388950174b","name":"Paulina Dobies"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/35538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/31"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=35538"}],"version-history":[{"count":2,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/35538\/revisions"}],"predecessor-version":[{"id":35540,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/35538\/revisions\/35540"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=35538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/categories?post=35538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/tags?post=35538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}